 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
3 News |  |
| 12345678910» |
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Journal, HEOR, Cost-effectiveness: Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. (Pubmed Central) - Jun 13, 2025
This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen.
- | Enrollment open: Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov) - Jun 6, 2025
P3, N=404, Recruiting, Sponsor: Fudan University
This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen. Not yet recruiting --> Recruiting
- || Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge. (Pubmed Central) - Jun 6, 2025
Despite ongoing efforts to identify biomarkers that may guide treatment decisions, no validated prognostic or predictive biomarkers are currently available for SCLC. This review summarizes the present role of adebrelimab in SCLC and outlines novel strategies aimed to further improve survival outcome.
- | RGL-270 / Shanghai Regenelead Therapies, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P1 trial: An open, multi-center phase I clinical study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of personalized new antigen RGL-270 single drug and combined with adebelimab in patients at high risk of recurrence after radical treatment of malignant solid tumors (EUDRACT) - Jun 6, 2025
P1, N=198, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Shanghai Regenelead Theraples,Co,Ltd.
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab-based therapy was used in solid tumors previously treated with PD-1 inhibitors: a single-arm, open, multicenter, exploratory clinical study (EUDRACT) - Jun 5, 2025
P2, N=20, Recruiting, Sponsor: Lianyungang First People's Hospital; Lianyungang First People's Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single-arm trial of adebrelimab combined with induction chemotherapy and concurrent chemoradiotherapy in the treatment of locally advanced head and neck squamous cell carcinoma with CPS>=1 (EUDRACT) - Jun 5, 2025
P4, N=74, Recruiting, Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
- | Aidixi (disitamab vedotin) / Pfizer, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A randomised controlled study comparing adebelimab plus Disitamab Vedotin and carboplatin versus nab-paclitaxel plus carboplatin in the neoadjuvant treatment of HER2-low breast cancer (EUDRACT) - Jun 5, 2025
P2, N=72, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital Sun Yat-sen University; Sun Yat-sen Memorial Hospital Sun Yat-sen University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial, Real-world evidence: A Prospective/Retrospective Real-World Study of Adebrelimab in Extensive-Stage Small Cell Lung Cancer (EUDRACT) - Jun 5, 2025
P=N/A, N=500, Recruiting, Sponsor: Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial (clinicaltrials.gov) - Jun 5, 2025
P2, N=30, Not yet recruiting, Sponsor: Jun Jia
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ (clinicaltrials.gov) - May 22, 2025
P2, N=30, Recruiting, Sponsor: Jiangsu Cancer Institute & Hospital
- ||| HS-10370 / Jiangsu Hansoh Pharma
New P1 trial: A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 9, 2025
P1, N=762, Not yet recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE. (Hall A - Posters and Exhibits; Poster Bd #: 500b) - May 1, 2025 - Abstract #ASCO2025ASCO_7402;
P2
Key secondary endpoints include overall survival (OS) and RFS, minimal residual disease (MRD), and patient-reported tolerability, and safety. Enrollment has begun, with six sites in mainland China participating.
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Apr 25, 2025
P2, N=60, Not yet recruiting, Sponsor: Fudan University
- |||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (clinicaltrials.gov) - Apr 24, 2025
P2, N=400, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Enrollment has begun, with six sites in mainland China participating. Not yet recruiting --> Recruiting
- Epidaza (chidamide) / Chipscreen, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5222;
P2
The ADEPT regimen showed promising antitumor activity and favorable tolerability as first-line therapy for locally advanced or metastatic pancreatic cancer. Further data from a large cohort and longer follow-up will be presented.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5220;
P2
Continued recruitment and follow-up are still ongoing. Clinical trail information: NCT06208462.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5122;
P2
Adebrelimab combined with lenvatinib showed promising antitumor activity and manageable safety profile in patients with unresectable or metastatic ICC who had progressed on or were intolerant to first-line chemotherapy. These findings provide a rationale for further investigation of this regimen as a second-line treatment option.
- Avastin (bevacizumab) / Roche, Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Airuituo (bevacizumab biosimilar) / Jiangsu Hengrui Pharma
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases. (Hall D2) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3410;
P2
Warranting further investigation in this highly aggressive disease. Clinical trial information: NCT04303988.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort. (Hall A - Posters and Exhibits; Poster Bd #: 82) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3320;
P2
The combination showed encouraging antitumor activity in unresectable or metastatic TNBC, irrespective of HER2 or PD-L1 expression status. Phase 2 preliminary efficacy summary.11HER2 and PD-L1 results were based on central lab assessment.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 383) - Apr 23, 2025 - Abstract #ASCO2025ASCO_2495;
P1/2, P3
A more favorable benefit-risk profile was observed for SHR-8068 given as a priming dose. A phase 3 trial (NCT06618664) is currently underway to further assess the combination as 1L treatment for aHCC.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas. (Hall A - Posters and Exhibits; Poster Bd #: 230) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1616;
P2
In previously untreated advanced TCs, preliminary results showed that adebrelimab plus nab-paclitaxel and carboplatin is effective and safe. It provides a new treatment option in pts with advanced TCs.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma
A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma. (Hall A - Posters and Exhibits; Poster Bd #: 442) - Apr 23, 2025 - Abstract #ASCO2025ASCO_1495;
P2
In terms of head and neck squamous cell carcinoma, Phase I clinical studies have confirmed the therapeutic safety and tumor activity of PD-L1 inhibitors. In this Phase II study, the PD-L1 inhibitor (Adebrelimab) demonstrated a favorable therapeutic response to locally advanced head and neck squamous cell carcinoma, and we look forward to final therapeutic data.
- |||| SHR-1826 / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (clinicaltrials.gov) - Apr 17, 2025
P1/2, N=400, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
In this Phase II study, the PD-L1 inhibitor (Adebrelimab) demonstrated a favorable therapeutic response to locally advanced head and neck squamous cell carcinoma, and we look forward to final therapeutic data. Not yet recruiting --> Recruiting
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, IBI-310 (ipilimumab biosimilar) / Innovent Biologics
Enrollment closed, Trial completion date: PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (clinicaltrials.gov) - Apr 16, 2025
P2, N=40, Active, not recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025
- || AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov) - Apr 14, 2025
P2, N=38, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: CSPAC-48: Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 8, 2025
P2, N=46, Not yet recruiting, Sponsor: Jin Xu
- ||||| HRS-7058 / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour (clinicaltrials.gov) - Apr 8, 2025
P2, N=300, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | New P3 trial: Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov) - Apr 7, 2025
P3, N=404, Not yet recruiting, Sponsor: Fudan University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy (clinicaltrials.gov) - Apr 7, 2025
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Adebrelimab combined with apatinib and chemotherapy in NSCLC treated with first-line PD-1 inhibitor therapy:a prospective, single-center, single-arm clinical study (EUDRACT) - Apr 2, 2025
P4, N=30, Not yet recruiting, Sponsor: Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Apatinib combined with adebrelimab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer:a prospective, single-arm study (EUDRACT) - Apr 2, 2025
P=N/A, N=20, Not yet recruiting, Sponsor: Nanjing Brain Hospital; Nanjing Brain Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: Prospective, Single arm, Exploratory Study of Adabelimumab Combined with Chemotherapy in Neoadjuvant/Translational Treatment of Small Cell Lung Cancer (EUDRACT) - Apr 2, 2025
P4, N=20, Not yet recruiting, Sponsor: The Second Hospital & Clinical Medical School. Lanzhou University; The Second Hospital & Clinical Medical School. Lanzhou University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: A single-arm, multicenter, exploratory clinical study of adebelimab in combination with chemotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma (EUDRACT) - Apr 2, 2025
P2, N=55, Not yet recruiting, Sponsor: Cancer Hospital Affiliated to Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Phase II clinical study of adebrelimab plus apatinib and SOX regimen for conversion therapy of advanced gastric or gastroesophageal junction adenocarcinoma (EUDRACT) - Apr 2, 2025
P2, N=49, Recruiting, Sponsor: Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A randomized, controlled, multicenter Phase II clinical study comparing neoadjuvant chemotherapy and immunotherapy and immuno-consolidationafter compared with immunoconsolidation after radical chemoradiotherapy for stage III potentially resectable NSCLC (EUDRACT) - Apr 2, 2025
P=N/A, N=92, Recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P4 trial: A single arm, exploratory study on the combination of Adebrelimab and Apatinib as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence after resection surgery (EUDRACT) - Apr 2, 2025
P4, N=30, Not yet recruiting, Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
- | AiTan (rivoceranib) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: An exploratory clinical study of radiotherapy sequential Adebrelimab and apatinib in the treatment of HR+/ HER2-advanced CDK4/6 inhibitors in patients with breast cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=30, Recruiting, Sponsor: The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A multicenter, cohort, prospective clinical study of adebelimab or carilizumab combined with icariin soft capsules and gemcitabine/cisplatin (GemCis) in the treatment of initially unresectable advanced biliary tract tumors (BTC) (EUDRACT) - Apr 2, 2025
P=N/A, N=60, Not yet recruiting, Sponsor: Lanzhou University Second Hospital (Second Clinical School); Lanzhou University Second Hospital (Second Clinical School)NIVERSITY
- | SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: An exploratory trial of SHR-A2102 in combination with Adebrelimab for the treatment of unresectable stage III non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P2, N=20, Not yet recruiting, Sponsor: Shanghai Chest Hospital; Shanghai Chest Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Prospective, single-center exploratory study of radical chemoradiotherapy (dCRT) combined with adbelizumab sequential adbelizumab combined with irinotecan liposomes in the treatment of unresectable advanced esophageal squamous cell carcinoma (EUDRACT) - Apr 2, 2025
P=N/A, N=5, Not yet recruiting, Sponsor: The Second Xiangya Hospital, Central South University; The Second Xiangya Hospital, Central South University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A Single-Center, Single-Arm Exploratory Clinical Study of Adebrelimab Combined with Paclitaxel Liposome and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=47, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of addebellizumab plus antilotinib as first-line treatment for STK11 and/or KEAP1-mutated advanced non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P=N/A, N=37, Recruiting, Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: High- and low-dose radiotherapy combined with Adebrelimab for advanced solid tumors after failure of first-line therapy (EUDRACT) - Apr 2, 2025
P2, N=33, Not yet recruiting, Sponsor: Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
Enrollment open: A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. (clinicaltrials.gov) - Apr 2, 2025
P2, N=49, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Sep 2025 Not yet recruiting --> Recruiting
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A single-arm, multicenter, exploratory clinical study of concurrent/sequential chemoradiotherapy and immunoconsolidation therapy for stage III non-resectable non-small cell lung cancer after chemoimmunotherapy induction therapy (EUDRACT) - Apr 2, 2025
P=N/A, N=37, Not yet recruiting, Sponsor: Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology; Union Hospital Affiliated to Tongji Medical Colleg
- ||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P2 trial: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2025
P2, N=400, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | New trial, IO biomarker: ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 25, 2025
P=N/A, N=300, Not yet recruiting, Sponsor: Nanjing Tianyinshan Hospital
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 20, 2025
P2, N=30, Recruiting, Sponsor: Nanfang Hospital, Southern Medical University
- |||| SHR-1826 / Jiangsu Hengrui Pharma
Enrollment open: A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC (clinicaltrials.gov) - Mar 19, 2025
P2, N=300, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: MA-GC-II-023: Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (clinicaltrials.gov) - Mar 18, 2025
P2, N=140, Not yet recruiting, Sponsor: China Medical University, China